HPTN studies evaluate innovative strategies in populations and geographical
regions that bear a disproportionate burden of risk including
cisgender women, adolescents and young people, cisgender
men who have sex with men (MSM), transgender people, and
people who use substances at sites located in Asia, Europe,
sub-Saharan Africa, and North and South America.

Since its inception in 1999, the HPTN has had a long history of
successfully conceptualizing, designing, and implementing,
complex clinical research studies with a focus on biomedical
interventions and integrated strategies to prevent HIV
acquisition and transmission with more than 65 clinical
research sites (CRSs) globally. 

The HPTN has long-standing partnerships with pharmaceutical companies, academic researchers worldwide, the Bill and Melinda Gates Foundation
and several other organizations. In addition, the HPTN has
forged collaborations to develop integrated strategies with
PEPFAR, the Centers for Disease Control and Prevention
(CDC) and both ministries and departments of health in several
countries. HPTN receives its funding from three U.S. National
Institutes of Health (NIH): the National Institute of Allergy and
Infectious Diseases, the National Institute of Mental Health,
and the National Institute on Drug Abuse.



HIV Prevention Trials Network (HPTN)

Similar companies